

Healthy Volunteers

## A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03222310 GP30057

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03222310 GP30057**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years & <= 55 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---